麻豆传媒

Armando Sardi, M.D., is a respected and renowned Surgical Oncologist who has been honored as a Top Doc in Baltimore magazine multiple times. He serves as Medical Director of The Institute for Cancer Care at Mercy and as Chief of Division of Surgical Oncology at Mercy Medical Center in Downtown Baltimore, Maryland. Dr. Sardi is one of Maryland’s leading surgical oncologists who use Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat late-stage, complex cancers of the abdominal region. Dr. Sardi has been performing HIPEC procedures since 1994 and is considered to be among the best doctors using the technique. This advanced heated chemotherapy procedure is often a life-saving treatment option for patients who have exhausted more traditional treatment plans for stomach cancer. Patients have traveled to Mercy Medical Center from points up and down the East Coast to destinations across the U.S., to seek out Dr. Sardi for his cancer expertise in the HIPEC treatment. Dr. Armando Sardi is a man whose professional focus is devoted to medical excellence, research and finding a cure for cancer. For his patients, Dr. Sardi’s personal concern and approach to their care are what helps them gain a positive outlook and confidence to face the challenges ahead. His cheerful smile and kind-hearted laugh immediately put patients at ease. And yet, his unyielding determination to give every patient the best possible chance to overcome their illness that ranks him among the best of the best. When other doctors have told patients there is no hope, Dr. Sardi tries even harder to beat the odds. Thanks to Dr. Sardi, the HIPEC procedure and other leading-edge treatment options, he has given patients so much more than hope. Patient after patient, year after year, have shared their stories at Mercy’s National Cancer Day Survivor Celebration and Mercy's annual Heat It to Beat It fundraising event. There are 3, 5, 10-year cancer survivors – each telling a heartwarming story of hope and survivorship. Dr. Sardi co-chair Mercy’s Cancer Committee and actively participates in The Tumor Board. These efforts allow cancer experts, specialists and key members of the healthcare team to discuss and collaborate on complex cancer cases to learn new and different ways to optimize resources, medical knowledge and treat patients so that long-term results will be improved. Dr. Sardi also plays a key role in the Mercy National Cancer Survivor Day festivities. This joyous and spirited celebration is more than a reunion of cancer survivors, it is a day when Dr. Sardi and the Mercy family rejoice with their patients and loved ones. Together they have been through a long and challenging cancer journey and together they delight in all the possibilities ahead. Dr. Armando Sardi, whose celebrated reputation has garnered local and international acclaim, has earned an international reputation for the advances he has made in the surgical oncology field and for his humanitarian efforts to care for the poor and underserved in third world countries. Dr. Sardi has been distinguished in Colombia, South America as one of the 100 Most Influential Expatriates – an honor received, in part, for the medical care he provides through the non-profit organization, Partners for Cancer Care and Prevention. This organization was the recipient of the Conquer Cancer Foundation's Inaugural International Innovation Grant. Dr. Armando Sardi has been recognized for his research, leadership and compassionate bedside manner. Some of his awards include: “Hispanic Hero Award for Excellence as a Medical/Social Entrepreneur” Presented by USHYEE “Gold Star Teamwork Award” Presented by The Sisters of Mercy in recognition of Gold Star performance Honored by Fusionarte as one of “100 Colombianos” who represent the talent, creativity, and perseverance of Colombia. Bogota, Colombia December 2012 Named by Baltimore Magazine a "Top Doctor" in the Surgical Oncology specialty Named by Castle Connelly Medical Ltd. a "Top Doctor" in Surgery Dr. Sardi founded the annual HEAT IT TO BEAT IT benefit walk in Baltimore to raise awareness about HIPEC and cancer treatment.

Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university鈥檚 partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics.

Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.

After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch.  He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. 

Clinical Expertise:
Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.

Dr. Gibson (nee Quinn) is an Endocrine Surgeon and Associate Professor of Surgery at Yale School of Medicine. Her clinical interests are surgery of the thyroid, parathyroid and adrenal gland, including minimally-invasive laparoscopic and retroperitoneoscopic surgical techniques. In addition, she serves as the Associate Clerkship Director for the Yale School of Medicine General Surgery Clerkship and is the Fellowship Director of the Endocrine Surgery Fellowship Program.
Her research interests include outcomes after minimally-invasive endocrine surgery (thyroid, parathyroid, adrenal), outpatient thyroidectomy and parathyroidectomy, intraoperative laryngeal nerve monitoring, and endocrine oncology. She obtained her MD from Virginia Commonwealth University School of Medicine, Richmond, VA. She was a postdoctoral research fellow in In Utero Stem Cell Transplantation at The Children's Hospital of Philadelphia (CHOP), Philadelphia, PA. She completed her training in General Surgery at Saint Barnabas Medical Center, Livingston, NJ, and Endocrine Surgery at Scott and White Memorial Hospital, Temple, TX.

Steven K. Libutti, MD, FACS was appointed Director of Rutgers Cancer Institute and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. On October 17th, 2024, Dr. Libutti was named the inaugural William N. Hait Director of Rutgers Cancer Institute. In addition to his leadership roles within Rutgers University, Dr. Libutti serves as Senior Vice President of Oncology Services for RWJBarnabas Health. He is also a Distinguished Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics, Rutgers School of Arts and Sciences. 
 
After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the National Cancer Institute (NCI) in surgical oncology. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. Following his time at the NCI, he served as the Director of the Montefiore Einstein Center for Cancer Care and as an Associate Director of the Albert Einstein Cancer Center for eight years prior to joining Rutgers and RWJBarnabas Health.
 
Dr. Libutti is an internationally known expert in the management of neuroendocrine tumors and Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas. The recipient of funding from the NCI for the past 25 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment as well as on a better understanding of the tumor suppressor genes MEN1 and FILIP1L. He has published over 300 peer reviewed journal articles, is Editor-in-Chief Emeritus of the Springer-Nature Journal Cancer Gene Therapy and holds eleven U.S. patents. Dr. Libutti has successfully navigated Rutgers Cancer Institute’s P30 CCSG Comprehensive Cancer Center Award through two competitive renewals, the most recent of which in 2023 achieved the Center’s highest score to date placing it among the top centers in the US.